Xadago

Chemical Namesafinamide
Dosage FormTablet (oral; 50 mg, 100 mg)
Drug ClassInhibitors
SystemMusculoskeletal, Nervous
CompanySupernus Pharmaceuticals
Approval Year2017

Indication

  • Indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes
Last updated on 4/21/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xadago (Safinamide) Prescribing Information.2017US WorldMeds, LLC, Louisville, KY